| Capelli, Debora |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
| WICKENHAUSER, Stefan |
| Recruiting | 3 | 350 | Europe, Canada, US, RoW | Selinexor, KPT-330, Placebo, Ruxolitinib | Karyopharm Therapeutics Inc | Myelofibrosis | 09/25 | 03/28 | | |
|
|
|
|
|
|
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
NCT04827719: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS |
|
|
| Active, not recruiting | 2 | 40 | Europe | BST-236 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
|
|
| Recruiting | 2 | 118 | Europe, Canada, US, RoW | Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA | Karyopharm Therapeutics Inc | Myelofibrosis, Moderate Thrombocytopenia | 04/26 | 10/28 | | |
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1/2 | 36 | Europe | Onureg + Venetoclax, CC-486 + ABT-199 | Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie | Untreated Myelodysplastic Syndrome | 11/25 | 11/28 | | |
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA |
|
|
| Recruiting | 1/2 | 150 | Europe | Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa | Groupe Francophone des Myelodysplasies, Celgene | MDS, Myelodysplastic Syndromes | 05/27 | 11/27 | | |
| PAPAYANNIDIS, Cristina |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
| Recruiting | 2/3 | 463 | Europe, US, RoW | Elenestinib, BLU-263, Placebo | Blueprint Medicines Corporation | Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis | 06/28 | 06/28 | | |
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
| Active, not recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
NCT05319587 / 2020-005493-10: Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 1/2 | 63 | Europe | Liposomal Annamycin, Cytarabine | Moleculin Biotech, Inc., Moleculin Biotech, Inc. | Leukemia, Myeloid, Acute | 08/23 | 04/25 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 70 | Europe, Canada, Japan, US, RoW | DSP-5336 | Sumitomo Pharma America, Inc. | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | 01/25 | 02/25 | | |
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
|
|
| Recruiting | N/A | 32 | Europe | bone marrow and/or peripheral blood samples withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All | 05/24 | 05/24 | | |
| Recruiting | N/A | 4000 | Europe | Registration into the STREAM platform | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 07/32 | 07/32 | | |
| Not yet recruiting | N/A | 100 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | VEXAS | 02/25 | 06/25 | | |
